BRPI0511427A - método de teste - Google Patents

método de teste

Info

Publication number
BRPI0511427A
BRPI0511427A BRPI0511427-6A BRPI0511427A BRPI0511427A BR PI0511427 A BRPI0511427 A BR PI0511427A BR PI0511427 A BRPI0511427 A BR PI0511427A BR PI0511427 A BRPI0511427 A BR PI0511427A
Authority
BR
Brazil
Prior art keywords
test method
sensory
social
physiological
present
Prior art date
Application number
BRPI0511427-6A
Other languages
English (en)
Inventor
Laura Corradini
Mark John Field
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0411140A external-priority patent/GB0411140D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of BRPI0511427A publication Critical patent/BRPI0511427A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

MéTODO DE TESTE. A presente invenção se refere ao campo da farmácia. A presente invenção mais particularmente revela um método para determinar os efeitos emocionais, sensoriais, fisiológicos, sociais e cognitivos de uma condição de dor em um animal não humano e adicionalmente revela um método para identificar pré-clinicamente produtos terapêuticos farmacêuticos os quais melhorem os efeitos emocionais, sensoriais, fisiológicos, sociais e cognitivos associados com uma condição de dor em um animal não humano.
BRPI0511427-6A 2004-05-19 2005-05-10 método de teste BRPI0511427A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0411140A GB0411140D0 (en) 2004-05-19 2004-05-19 Assay method
US58826104P 2004-07-14 2004-07-14
PCT/IB2005/001403 WO2005114181A2 (en) 2004-05-19 2005-05-10 Assay method

Publications (1)

Publication Number Publication Date
BRPI0511427A true BRPI0511427A (pt) 2007-12-11

Family

ID=35428994

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511427-6A BRPI0511427A (pt) 2004-05-19 2005-05-10 método de teste

Country Status (7)

Country Link
US (1) US20090214426A1 (pt)
EP (1) EP1751547A2 (pt)
JP (1) JP2007538250A (pt)
BR (1) BRPI0511427A (pt)
CA (1) CA2566468A1 (pt)
MX (1) MXPA06013402A (pt)
WO (1) WO2005114181A2 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203198A3 (en) * 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
WO2004000883A1 (en) * 2002-06-24 2003-12-31 Bayer Healthcare Ag Regulation of human growth hormone-releasing hormone receptor

Also Published As

Publication number Publication date
WO2005114181A2 (en) 2005-12-01
JP2007538250A (ja) 2007-12-27
CA2566468A1 (en) 2005-12-01
MXPA06013402A (es) 2007-01-23
EP1751547A2 (en) 2007-02-14
US20090214426A1 (en) 2009-08-27
WO2005114181A3 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
Jurcau Insights into the pathogenesis of neurodegenerative diseases: Focus on mitochondrial dysfunction and oxidative stress
Krivanek et al. Promoting successful cognitive aging: a ten-year update
Brody et al. Brief report: self-harm is associated with immature defense mechanisms but not substance use in a nonclinical Scottish adolescent sample
Cabungcal et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia
Bluth et al. A pilot study of a mindfulness intervention for adolescents and the potential role of self-compassion in reducing stress
Bizik et al. Allostatic load as a tool for monitoring physiological dysregulations and comorbidities in patients with severe mental illnesses
Crofford Pain management in fibromyalgia
Ward et al. Behavioral and monoamine changes following severe vitamin C deficiency
O'Neil et al. Preventing mental health problems in offspring by targeting dietary intake of pregnant women
Brenner et al. Evolutionary mismatch and chronic psychological stress
Mayorga et al. A randomized study to evaluate the analgesic efficacy of a single dose of the TRPV1 antagonist mavatrep in patients with osteoarthritis
Batstra et al. Holding the line against diagnostic inflation in psychiatry
Ancora et al. Follow-up at the corrected age of 24 months of preterm newborns receiving continuous infusion of fentanyl for pain control during mechanical ventilation
CY1119122T1 (el) Θεραπευτικη αναπληρωση και εμπλουτισμος της λιπανσεως της οφθαλμικης επιφανειας
BR112013017446A2 (pt) composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona
Dowlati et al. Selective dietary supplementation in early postpartum is associated with high resilience against depressed mood
Larralde et al. Capillary malformation–arteriovenous malformation: a clinical review of 45 patients
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
ZA201907466B (en) Products and methods for therapeutic administration of microorganisms to non-human animals
Anderson et al. Pharmacological activation of kappa opioid receptors: aversive effects in adolescent and adult male rats
EA201101706A1 (ru) Лекарственное средство на основе дииндолилметана(dim) с повышенной биодоступностью и его использование в лечении гиперпластических и воспалительных заболеваний человека
Ledesma-Corvi et al. Exploring pharmacological options for adolescent depression: a preclinical evaluation with a sex perspective
Atli et al. Evidence for neurotoxicity associated with amoxicillin in juvenile rats
Qiao et al. Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model
Marek et al. Targeting premeal anxiety in eating disordered clients and normal controls: A preliminary investigation into the use of mindful eating vs. distraction during food exposure

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.